Adriana Matutino Kahn, MD
Assistant Professor of Medicine (Medical Oncology)DownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileContact Info
Center for Breast Cancer
300 George St, Room 120
New Haven, CT 06511
United States
About
Titles
Assistant Professor of Medicine (Medical Oncology)
Biography
Dr. Adriana Kahn is an Assistant Professor of Medicine (Medical Oncology) and cares for patients as part of the Center for Breast Cancer and the Drug Development Department at Yale Cancer Center. Dr. Kahn completed a fellowship in Medical Oncology at the Yale School of Medicine. She completed residency at the University of Connecticut. Prior to coming to the United States, she completed a fellowship in Breast Cancer in Canada. She completed residency and medical oncology fellowship at the Universidade de Sao Paulo, Brazil. She received her medical degree from the Universidade Federal da Bahia, Brazil.
Dr. Kahn’s research focuses on Breast Cancer and Drug Development. She was awarded the 2023 Robert A. Winn Diversity in Clinical Trials Career Development Award from the American Association of Cancer Research Career (AACR), as well as the 2023 Young Investigator Award from the American Society of Clinical Oncology (ASCO) for her ongoing work. She is the author of multiple peer-reviewed publications and poster presentations in national and international conferences. She is the author of investigator-initiated clinical trials and works as principal investigator of ongoing clinical trials at the Yale Cancer Center. Dr. Kahn is known to be a competent, caring and compassionate physician.
Appointments
Medical Oncology
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- Medical Oncology Fellow
- Yale School of Medicine (2023)
- Internal Medicine Resident
- University of Connecticut (2021)
- Breast Cancer Fellow
- University of Calgary (2018)
- Medical Oncology Fellow
- Universidade de São Paulo (2016)
- Internal Medicine Resident
- Universidade de São Paulo (2013)
- MD
- Universidade Federal da Bahia (2010)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Adriana Matutino Kahn's published research.
Publications Timeline
A big-picture view of Adriana Matutino Kahn's research output by year.
Lajos Pusztai, MD, DPhil
Kim Blenman, PhD, MS
Andrea Silber, MD
Kerin Adelson, MD
Naing Lin Shan, MBBS, PhD, MS
Neal Fischbach, MD
27Publications
144Citations
Publications
Featured Publications
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsImmune-related adverse eventsTriple-negative breast cancerNon-AA patientsEvent-free survivalPhase I/II clinical trialsClinical trialsNeoadjuvant chemotherapyOverall survivalAA patientsEarly-stage triple-negative breast cancerIncidence of irAEsPathologic complete response rateSignificant associationMultivariate logistic regression analysisTumor-infiltrating lymphocyte countsComplete response ratePrimary efficacy endpointPD-L1 statusProportional hazards modelLogistic regression analysisAfrican American womenEFS ratesNeoadjuvant immunotherapyEfficacy endpointAdverse eventsClinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer
Silva S, Pereira A, Marta G, de Barros Lima K, de Freitas T, Matutino A, de Azevedo Souza M, de Azevedo R, de Viveiros P, da Silva Lima J, Filassi J, de Andrade Carvalho H, Piato J, Mano M. Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer. The Breast 2017, 38: 39-44. PMID: 29223797, DOI: 10.1016/j.breast.2017.11.012.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsPost-operative radiation therapyDisease-free survivalBetter disease-free survivalNeoadjuvant chemotherapyBreast cancerOverall survivalAdvanced breast cancerClinical stage IIIBetter overall survivalAdvanced BC patientsTherapy delayBC patientsClinical impactEarly initiationRadiation therapyStage IIIPatientsSurgeryOptimal timingWeeksChemotherapyFirm conclusionsCancerSurvivalInitiationIntratumour heterogeneity, from hypothesis to the clinic
Shan NL, Kahn A, Pusztai L. Intratumour heterogeneity, from hypothesis to the clinic. British Journal Of Cancer 2022, 128: 459-460. PMID: 36216884, PMCID: PMC9938204, DOI: 10.1038/s41416-022-02008-w.Commentaries, Editorials and LettersCitationsMeSH Keywords and ConceptsCDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
Matutino A, Amaro C, Verma S. CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. Therapeutic Advances In Medical Oncology 2018, 10: 1758835918818346. PMID: 30619511, PMCID: PMC6299331, DOI: 10.1177/1758835918818346.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTriple-negative breast cancerProgression-free survivalBreast cancerCDK4/6 inhibitorsHormone receptor-positive HER2-negative diseaseCyclin-dependent kinase 4/6 inhibitorsPositive human epidermal growth factor receptor 2Human epidermal growth factor receptor 2Epidermal growth factor receptor 2HER2-negative diseaseGrowth factor receptor 2Metastatic breast cancer therapyNegative breast cancerBreast cancer therapyFactor receptor 2Preclinical evidenceClinical dataReceptor 2Later linesHormone receptorsCancerCancer therapyCell linesInhibitorsCDK inhibitorsThe impact of age in the quality of life of patients diagnosed with breast cancer after curative treatment.
Matutino A, Lewis J, Verma S, Taylor A, Huber S, Chen G. The impact of age in the quality of life of patients diagnosed with breast cancer after curative treatment. Journal Of Clinical Oncology 2018, 36: 67-67. DOI: 10.1200/jco.2018.36.7_suppl.67.Peer-Reviewed Original ResearchCitationsConceptsBreast cancerDifferent age groupsCurative treatmentAge groupsRetrospective cross-sectional analysisAnti-hormonal therapyBreast conserving surgeryCancer Patient QuestionnaireQuality of lifeImpact of ageCross-sectional analysisHigh financial burdenSurvivorship careConserving surgeryPatient questionnaireCurative therapySecond cancersLess painQOL scoresInvasive diseaseQoL dataHigh prevalenceStage 0Radiation therapyOngoing anxietyStrategies to mitigate the toxicity of cancer therapeutics
Kahn AM, Blenman KRM, Sonis ST, Lustberg MB. Strategies to mitigate the toxicity of cancer therapeutics. Advances In Cancer Research 2022, 155: 215-244. PMID: 35779875, DOI: 10.1016/bs.acr.2022.02.006.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAromatase inhibitor-induced musculoskeletal symptomsChemotherapy-induced peripheral neuropathyCancer-related cognitive impairmentCancer treatment symptomsOral mucosal toxicityImmune checkpoint inhibitionTyrosine kinase inhibitorsCancer therapeuticsGastrointestinal toxicityMucosal toxicityAdverse eventsHormone therapySystemic therapyTreatment toxicityPeripheral neuropathyCheckpoint inhibitionSymptom managementMusculoskeletal symptomsRenal toxicityTreatment symptomsOcular toxicityTreatment modalitiesTraditional chemotherapyCognitive impairmentMonoclonal antibodiesComparison of clinical characteristics and survival of metastatic breast cancer patients in United States according to insurance status as compared to outcomes in Canada.
Matutino A, Pereira A, Kornaga E, Lupichuk S, Verma S. Comparison of clinical characteristics and survival of metastatic breast cancer patients in United States according to insurance status as compared to outcomes in Canada. Journal Of Clinical Oncology 2018, 36: e18617-e18617. DOI: 10.1200/jco.2018.36.15_suppl.e18617.Peer-Reviewed Original ResearchCitationsIntratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer
Kahn A, Golestani R, Harigopal M, Pusztai L. Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer. Breast Cancer Research And Treatment 2023, 201: 289-298. PMID: 37378695, DOI: 10.1007/s10549-023-06977-1.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsTriple-negative breast cancerPD-L1 expressionBreast cancerPD-L1Metastatic triple-negative breast cancerPD-L1 positive casesEarly-stage breast cancerPD-L1 protein expressionImmune checkpoint inhibitorsPD-L1 positivityPD-L1 statusProtein expressionWhole study populationPrimary breast tumorsNegative breast cancerConcordant negative resultsCheckpoint inhibitorsMultiple biopsiesPositive cancersCohen's kappa coefficientStudy populationE1L3N antibodyDiscordance rateBreast tumorsPositive casesOutcomes of acute pulmonary embolism in hospitalized patients with cancer.
Shalaby K, Kahn A, Silver ES, Kim MJ, Balakumaran K, Kim AS. Outcomes of acute pulmonary embolism in hospitalized patients with cancer. BMC Pulm Med 2022, 22: 11. PMID: 34986814, DOI: 10.1186/s12890-021-01808-9.Peer-Reviewed Original ResearchSurvival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status.
Savard MF, Kornaga EN, Kahn AM, Lupichuk S. Survival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status. Curr Oncol 2022, 29: 383-391. PMID: 35049708, DOI: 10.3390/curroncol29010034.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
honor Robert A. Winn Diversity in Clinical Trials Career Development Award
International AwardAmerican Association of Cancer ResearchDetails08/02/2023United Stateshonor Young Investigator Award
International AwardAmerican Society of Clinical Oncology (ASCO)Details06/02/2023United States
Clinical Care
Overview
Clinical Specialties
Medical Oncology
Fact Sheets
Breast Cancer
Learn More on Yale MedicineCancer
Learn More on Yale MedicineDiagnosing Cancer
Learn More on Yale Medicine
Board Certifications
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2021
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews & Links
News
- October 07, 2024
Caring for Metastatic Breast Cancer: A Conference for Patients and Caregivers
- July 17, 2024Source: Everyday Health
Is My Breast Rash a Sign of Cancer?
- June 19, 2024Source: MedPage Today
Breast Cancer Highlights From ASCO 2024
- January 29, 2024
Comprehensive Breast Cancer Care at Smilow Cancer Hospital in New Haven
Get In Touch
Contacts
Appointment Number
Mailing Address
Center for Breast Cancer
300 George St, Room 120
New Haven, CT 06511
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.